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A 38-year-old woman with Eisenmenger’s syndrome underwent bilateral 
living-donor lobar lung transplantation and simultaneous closure of atrial septal 
defect. The grafts were a right lower lobe from her husband and a left lower lobe 
from her brother. Although only two lobes were implanted, the dramatic 
improvement in pulmonary hemodynamics has been well maintained for more than 
5 years. Living-donor lobar lung transplantation and simultaneous cardiac repair 
may be one of the therapeutic options for adult Eisenmenger’s syndrome with 
























Lung or heart-lung transplantation remain the treatment of last resort for adult 
patients with Eisenmenger’s syndrome who fail medical therapy. Living-donor lobar 
lung transplantation (LDLLT) was developed to mismatch between supply and 
demand for those patients awaiting cadaveric lung transplantation.1 We report the 
first successful LDLLT and simultaneous closure of atrial septal defect (ASD) for 
adult Eisenmenger’s syndrome. 
CASE REPORT 
An adult female patient was diagnosed with ASD in her childhood but did not 
receive cardiac repair. In 1996, at the age of 31 years old, she delivered a normal 
baby. Soon after the delivery, symptoms of dyspnea occurred during exercise and she 
was diagnosed with Eisenmenger’s syndrome. In 2001, at the age of 36, she further 
developed pulmonary thromboembolism and pulmonary infarction. In 2003, at the 
age of 38, she became wheel chair bound and transferred to Okayama University 
Hospital for possible lung transplantation. On admission, she was markedly 
cyanotic and her arterial blood gas revealed a pH of 7.39, PaO2 of 35.0 mmHg, and 
PaCO2 of 36.2 mmHg, with 3 L/min oxygen administration via a nasal cannula. 
Chest X-ray showed dilated heart and pulmonary artery (PA) shadow (Figure 1A). 
The right heart catheterization performed a year ago revealed highly elevated 
pulmonary arterial pressure (systolic/diastolic/mean: 115/42/72). Two-dimensional 
echocardiography demonstrated a dilated dyskinetic right ventricle and D-shaped 
left ventricle. By color Doppler echocardiography, bidirectional shunt through the 
atrial septal defect with a diameter of 2.8 cm and massive tricuspid regurgitation 
were demonstrated. Enhanced CT scan showed enlarged pulmonary artery (PA), 
pulmonary thromboembolism and pulmonary infarction.  
The surgical options were discussed with the patient and the family, and they were 
willing to proceed with LDLLT, which they understood to be the first case for adult 




Eisenmenger’s syndrome. The case was carefully discussed and approved by the 
Lung Transplant Evaluation Committee at Okayama University Hospital. 
On April 30, 2003, she underwent LDLLT at the age of 38, with a right lower lobe 
from her husband (36 years old) and a left lower lobe from her brother (34 years old). 
The height and weight was 146 cm, 40.2 kg for the recipient, 178 cm, 93.0 kg for the 
husband, and 169 cm, 74.0 kg for the brother. The total force vital capacity (FVC) of 
the two grafts was estimated to be 2,352 ml, or 89.8% of the recipient’s predicted 
FVC according to the formula we have proposed.2 
 Because the patient’s hemodynamics was unstable, cardiopulmonary bypass was 
instituted with bicaval venous drainage before completing the bilateral hilar 
dissection. Under cold cardioplegic arrest, the right atrium was opened. We closed 
the ASD, 25×30 mm, with a pericardial patch. After the aortic clamp was removed, 
bilateral pneumonectomy was performed. Pulmonary thromboemoblism was seen 
bilaterally distal to the first branch of PA which was removed at pneumonectomy. 
Two lobes were then implanted in the manner previously described.1 The PA 
anastomosis was challenging due to marked size discrepancy between the 
recipient’s main PA and the donor’s lobar PA. The recipient PA was partially closed 
by placing tacking stitches and then the end-to-end anastomosis was carried out. 
Cardiopulmonary bypass could be removed without any sign of lung edema after 
reperfusion. 
Postoperative immunosuppresion was a triple drug therapy consisting of 
tacrolimus, mycophenolate mofetil and prednisone. Two episodes of acute rejection 
were successfully treated by steroid pulse. The patient was completely weaned from 
the respirator on day 22 and discharged from the hospital on day 48 without oxygen 
inhalation.  
The dramatic improvement in pulmonary hemodynamics was seen one month 
after LDLLT and has been well maintained for more than 5 years (Table I). Her 




chest X-ray demonstrated well-expanded grafts without cardiomegaly (Figure 1B). 
Although she developed right unilateral bronchiolitis obliterans syndrome at 4 
years, she is able to carry out normal activities for more than 6 years since she 
received the LDLLT. 
Postoperative course was uneventful in both donors and they have returned to 
their previous life styles during the 6-year observation period. 
DISCUSSION 
There are three transplant options for Eisenmenger’s syndrome; single lung 
transplantation (SLT), bilateral lung transplantation (BLT), and heart-lung 
transplantation (HLT). Cardiac repair with BLT3 appears to have a better 
post-operative course than SLT4, but carries potential morbidity associated with 
longer cardiopulmonary bypass. HLT5 is a simpler operation than BLT with repair 
of congenital heart disease, but requires allocation of two organs from the scarce 
donor organ supply, and adds risk of cardiac graft coronary vasculopathy and is less 
tolerant of ischemic time.  
LDLLT was pioneered by the University of Southern California group to deal with 
the shortage of cadaveric donors.1 They originally applied this procedure almost 
exclusively to cystic fibrosis patients and then expanded the indications to other 
diagnoses including pediatric patient with pulmonary arterial hypertension (PAH).6 
Since 2000, we have applied this procedure to both pediatric and adult patients with 
PAH.7  
It has been suggested that adults with Eisenmenger’s syndrome have a more 
favorable hemodynamic profile and prognosis than adults with idiopathic PAH.8 In 
contrast, the 5-year survival after BLT or HLT remains to be approximately 50% 
according to the registry of ISHLT.9 Our patient with Eisenmenger’s syndrome was 
critically ill due to associated pulmonary thromboembolism. The realistic option for 
this patient was only to receive LDLLT in Japan, where obtaining brain death 




donors is extremely difficult. The ethical concerns of LDLLT present an obvious 
dilemma. This procedure subjects two healthy donors to a right or left lower 
lobectomy associated with an expected risk of death between 0.5% to 1%, a 
complication rate of 10-20%, and the inevitable 15% reduction in pulmonary 
function. While there have been no deaths in the donor cohort, these disadvantages 
are to be carefully explained to the potential donors during the process of obtaining 
informed consent. Because of these ethical concerns, we accept only very sick 
patients as LDLLT recipients. 
Because limited amount of lung tissue is implanted in LDLLT, size matching is an 
important issue. Matsuda and his colleagues reported successful LDLLT and 
simultaneous closure of ASD for an 11-year-old boy with irreversible pulmonary 
hypertension.10 The present case was the first successful LDLLT for adult 
Eisenmenger’s syndrome. Luckily, our patient had two male donors who were taller 
than her and the total FVC of the two grafts was estimated to be 89.9% of the 
recipient’s predicted FVC. Although only two lobes were implanted, the dramatic 
improvement in pulmonary hemodynamics has been well maintained for more than 
5 years. Although her FEV1 decreased at 5 years due to right unilateral 
bronchiolitis obliterans syndrome, she is maintaining a good quality of life because 
her unaffected left graft is functioning normally. 
LDLLT and simultaneous cardiac repair may be one of the therapeutic options for 
adult Eisenmenger’s syndrome with simple congenital heart disease. 
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Figure 1. Chest X-ray of a 38-year-old female with Eisenmenger’s syndrome. (A) 




TABLE 1. Patient data
Posttransplant
Pretransplant 2 months 1year 3 years 5 years
PAP (mmHg) 115/44 (72) 36/12 (20) 32/9 (17) 23/6 (13) 16/10 (13)
PCWP (mmHg) 8 11 10 8 7
CVP (mmHg) 7 3 0 3 1
PaO2 (mmHg) 35.0 (O2 3L/min) 99.3 100.8 79.0 93.7
PaCO2 (mmHg) 36.2 (O2 3L/min) 42.4 33.2 33.7 39.2
VC (mL) 2310 1640 1800 2020 2200
%VC (%) 86.8 61.7 68.2 77.7 84.9
FEV1 (mL) 1620 1510 1600 1790 1270
WHO class Ⅳ Ⅰ Ⅰ Ⅰ Ⅱ
PAP , pulmonary arterial pressure; PCWP , pulmonary capillary wedge pressure
CVP, central venous pressure; PaO 2 , arterial oxygen tension; PaCO 2 , arterial carbon dioxide tension
VC, vital capacity; FEV1, forced expiratory volume in one second

